Our previous gene expression profiling (GEP) analysis showed that NEK2A expression was significantly upregulated in several types of human cancer samples compared to normal cells, including multiple myeloma, myeloid leukemia, breast cancer, lung adenocarcinoma, mantle cell lymphoma, mesothelioma, head and neck squamous cell carcinoma, bladder carcinoma, glioblastoma, T-cell acute lymphoblastic leukemia, colon carcinoma, hepatocellular carcinoma, melanoma, and ovarian adenocarcinoma [12]. This evidence concerns the gene NEK2 and lung adenocarcinoma.